Second-generation Sequencing Guides the Treatment of Severe Pneumonia
Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
Investigators plan to conduct the participants level, 1:1 randomized trial at the Central ICU
and respiratory ICU of Xiangya Hospital in Changsha, China, from January 1, 2018 to December
31, 2019. Participants with initial diagnosis of severe pneumonia will be first treated with
empiric therapy, after 48-72 hours, the participants's condition will be evaluated, and
participants who will have been initially cured and died should be excluded.The participants
who will have failed the initial treatment will be then randomly divided into two groups: the
NGS group and the conventional treatment group. Bronchoalveolar lavage fluid will be taken by
bedside bronchoscopy when the participants underwent nasal high-flow oxygen therapy,
non-invasive ventilation, and invasive ventilation,or venous blood will be taken for
examination. Participants in the NGS group will be tested for both NGS and conventional
pathogens, however, the routine group will be only routinely tested. According to the
pathogen results, participants with non-severe pneumonia will be excluded, and medication
should be adjusted under the joint guidance of infectious and respiratory specialists. Then
investigators will compare the first outcome: 28-day mortality, and secondary outcome: ICU
hospitalization time, mechanical ventilation time, Hospitalization costs, antibiotic use
costs, SOFA scores, CURB-65 scores, APACHE scores, and other clinical indicators.